Public health officials reiterated the importance of vaccines after seeing a rise in circulating levels of respiratory syncytial virus (RSV).

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for ...

The federal government will place RSV vaccines on the national immunisation program, as 12,000 babies are hospitalised with ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

In 2025, eligible pregnant women will be able to receive the respiratory syncytial virus (RSV) vaccine for free under the ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...